Genmab (GMAB) Q4 2025: Proprietary Medicine Sales Jump 54% as Pipeline Readouts Set Up 2027 Launch Wave
Genmab’s proprietary medicines surged in 2025, with Epkinley and TIVDAC driving a 54% sales increase, while the late-stage pipeline sets up a high-stakes 2026 for pivotal data readouts. With blockbuster ambitions for Epkinley, RENA-S, and pitocentumab, the company is scaling commercialization and R&D investment, but faces pivotal regulatory and clinical inflection points ahead.
Summary
- Proprietary Portfolio Acceleration: Epkinley and TIVDAC growth signals successful transition to a diversified, high-margin revenue mix.
- Pipeline Inflection Year: Multiple registrational readouts in 2026 will define future launch cadence and market expansion.
- Capital Allocation Discipline: Reinvestment in late-stage assets balanced with profitability and deleveraging targets.
Performance Analysis
Genmab delivered robust 2025 results, with total revenue up 19% to $3.7 billion, underpinned by both royalty streams and rapid growth in sales of proprietary medicines. Notably, proprietary brands contributed $632 million, up 54% year-over-year, now representing 28% of total revenue growth and demonstrating the company’s successful pivot from a royalty-heavy model toward direct commercialization.
Epkinley, bispecific antibody for B-cell malignancies, led the charge with $468 million in sales, up 67% YoY, buoyed by global regulatory approvals and new indications. TIVDAC, antibody-drug conjugate (ADC) for cervical cancer, also posted strong gains, with $164 million in sales and 26% YoY growth. Operating expenses rose 13%, reflecting targeted investment in commercialization and pipeline advancement, yet operating profit expanded to $1.26 billion, highlighting operating leverage as the business scales.
- Commercial Execution: Four launches across three continents, including first independent launches in Europe, signal maturing go-to-market capability.
- Revenue Mix Shift: Higher proportion of sales from proprietary medicines enhances margin profile and future earnings power.
- Pipeline-Driven Cost Step-Up: Increased R&D and launch readiness spend is deliberate, supporting late-stage assets with multi-billion potential.
Genmab’s financials reflect a business in transition, balancing near-term profitability with long-term investment in pipeline and commercial infrastructure. The company’s ability to grow operating profit while scaling investment is a key differentiator among mid-cap biotech peers.
Executive Commentary
"With our five combined breakthrough therapy designations, these three programs have multi-billion dollar potential, and they firmly underpin our long-term growth."
Jan van der Winkel, Chief Executive Officer
"Here, we are choosing to reinvest part of the operating leverage now to strengthen future growth drivers, while continuing to manage costs actively and maintain profitability discipline. This balance reinvesting to support growth while driving substantial profitability is a core feature of our operating model."
Anthony Pagano, Chief Financial Officer
Strategic Positioning
1. Proprietary Commercial Model Scaling
Genmab’s expansion into direct commercialization is yielding results, with new launches in the US, Japan, and Europe and a shift to a wholly owned model. The company is now present in key EU markets, supporting future launches and improving control over pricing and market access.
2. Blockbuster Pipeline with Near-Term Catalysts
Epkinley, RENA-S, and pitocentumab, each with breakthrough therapy designations, anchor Genmab’s late-stage pipeline. Up to six registrational data readouts in 2026 could unlock multiple launches in 2027, expanding the addressable patient population by orders of magnitude, especially in B-cell lymphomas and gynecologic cancers.
3. Disciplined Capital Allocation and M&A Integration
The Merus acquisition brought pitocentumab into the fold, broadening the late-stage portfolio. Management is balancing integration, pipeline acceleration, and a commitment to deleveraging, with a target of gross leverage below 3x by 2027, while maintaining a $1.15 billion operating profit target for 2026.
4. R&D Focus on Next-Generation Antibody Platforms
The early-stage pipeline is now concentrated on bispecifics, ADCs, and hexabody technologies, with recent INDs reflecting this focus. Leadership is prioritizing high-impact assets and combinatorial strategies, while remaining open to external innovation via selective M&A.
5. Regulatory and Label Expansion Strategy
Genmab is leveraging outpatient data and combination regimens to expand Epkinley’s label into earlier lines of therapy and broader patient populations. Regulatory discussions are ongoing to ensure confirmatory studies align with evolving standards and maximize the probability of approval across geographies.
Key Considerations
Genmab’s 2025 results highlight a business at a strategic crossroads, with execution risk and opportunity tightly linked to late-stage pipeline outcomes and commercial scaling.
Key Considerations:
- Epkinley’s Expansion Path: Regulatory success in earlier lines of B-cell lymphoma could unlock a fivefold increase in addressable patients, but hinges on pivotal trial outcomes and agency acceptance of confirmatory studies.
- RENA-S and Pitocentumab Launch Readiness: Both assets carry multi-billion dollar ambitions, but require successful data and rapid market entry to displace entrenched therapies.
- Commercial Infrastructure Build: Genmab’s ability to scale sales and marketing, especially in Europe, will be tested as launches accelerate and competitive intensity rises.
- Margin Management Amid Investment: Operating leverage is positive, but further R&D and launch investments could pressure near-term margins if revenue ramps are delayed.
Risks
Genmab’s trajectory is highly sensitive to late-stage clinical trial outcomes and regulatory decisions, particularly for Epkinley’s label expansion and the pivotal readouts for RENA-S and pitocentumab. Any failure to achieve positive data or secure timely approvals could materially impact growth expectations and market share ambitions. Additionally, integration of the Merus pipeline and execution of new launches in unfamiliar geographies introduce operational and competitive risk. Macroeconomic volatility and pricing pressures, especially in Europe, remain ongoing watchpoints.
Forward Outlook
For 2026, Genmab guided to:
- 14% total revenue growth at the midpoint, led by proprietary medicine momentum and royalty portfolio stability.
- Operating profit of $1.15 billion, balancing increased R&D and commercial investment with margin discipline.
For full-year 2026, management maintained guidance:
- Darzalex net sales in the $15.6 billion to $16.4 billion range, supporting royalty base.
Management highlighted several factors that will shape the year:
- Six potential pivotal data readouts in the late-stage pipeline, setting up 2027 launches.
- Continued integration of Merus and acceleration of pitocentumab development.
Takeaways
Genmab’s 2025 execution validates its transition to a fully integrated oncology biotech, but the next 12 months will be decisive as pivotal readouts and regulatory interactions determine the commercial fate of the lead pipeline assets.
- Pipeline Data is Pivotal: Success or delay in key registrational trials for Epkinley, RENA-S, and pitocentumab will define the company’s growth curve and competitive positioning through the decade.
- Margin and Capital Discipline: Management’s ability to scale investment while maintaining profitability and deleveraging will be tested as launch activity ramps.
- Commercial Scaling Watchpoint: Investors should monitor execution in new markets and uptake of proprietary medicines as a leading indicator for future platform leverage.
Conclusion
Genmab enters 2026 with strong momentum in proprietary medicine sales and a pipeline dense with near-term catalysts. The company’s ability to convert clinical and regulatory milestones into commercial success, while maintaining margin discipline and integration pace, will determine whether it delivers on its blockbuster ambitions and sustains high-quality growth into the next decade.
Industry Read-Through
Genmab’s results underscore a broader oncology trend: biotechs with differentiated antibody platforms and integrated commercial models are capturing more value as they move beyond royalty dependence. The competitive bar in B-cell malignancies and gynecologic cancers is rising, with regulatory agencies scrutinizing endpoints and combination strategies. Peers should note the importance of label expansion, first-mover advantage, and disciplined capital allocation as pipelines mature. The focus on ADCs, bispecifics, and combinatorial regimens reflects where innovation and value creation are converging across oncology biotech.